A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
# | Schellong Test | Pulse Pressure | Systolic Diff. | Pulse Rate Diff. | Pulse Pressure Diff. | |||||||||||||||||||||
S | D | P | S0 | D0 | P0 | S10 | D10 | P10 | ||||||||||||||||||
1 | 134 | 89 | 53 | 127 | 97 | 64 | 130 | 95 | 63 | 45 | 30 | 35 | 7 | 4 | 11 | 10 | 15 | 10 | ||||||||
2 | ||||||||||||||||||||||||||
3 | ||||||||||||||||||||||||||
4 | 109 | 62 | 55 | 108 | 68 | 74 | 105 | 71 | 69 | 47 | 40 | 34 | 1 | 4 | 19 | 14 | 7 | 13 | ||||||||
5 | 94 | 69 | 56 | 107 | 77 | 83 | 102 | 80 | 68 | 25 | 30 | 22 | −13 | −8 | 27 * | 12 | −5 | 3 | ||||||||
6 | 102 | 69 | 80 | 90 | 75 | 94 | 98 | 79 | 98 | 33 | 15 | 19 | 12 | 4 | 14 | 18 | 18 * | 14 | ||||||||
7 | 146 | 91 | 86 | 137 | 98 | 106 | 142 | 98 | 101 | 55 | 39 | 44 | 9 | 4 | 20 | 15 | 16 * | 11 | ||||||||
8 | 134 | 84 | 71 | 123 | 85 | 85 | 126 | 96 | 87 | 50 | 38 | 30 | 11 | 8 | 14 | 16 | 12 | 20 * | ||||||||
9 | 106 | 70 | 62 | 106 | 79 | 81 | 108 | 83 | 72 | 36 | 27 | 25 | 0 | −2 | 19 | 10 | 9 | 11 | ||||||||
10 | 97 | 58 | 76 | 85 | 55 | 110 | 86 | 60 | 98 | 39 | 30 | 26 | 12 | 11 | 34 * | 22 * | 9 | 13 | ||||||||
# | DHI | HADS | SDS | POUNDing | Migrane | MIDAS | Romberg Rate | Rubber Ratio | Total Length | Caloric Testing | ||||||||||||||||
A | D | Screener | (Velocity, Rubber) | (Eyes Closed, Velocity) | (Eyes Opened) [cm] | (Eyes Closed) [cm] | L (degree/s) | R (degree/s) | CP% | |||||||||||||||||
1 | 12 | 4 | 5 | 35 | 0 | 0 | 1 | 1.63 | 1.45 | 85.95 | 97.67 | 36.5 | 48 | 14 | ||||||||||||
2 | 56 | 3 | 9 | 39 | 0 | 0 | 1 | 1.29 | 1.61 | 74.03 | 84.71 | 13.5 | 17 | 11 | ||||||||||||
3 | 28 | 5 | 7 | 37 | 1.53 | 1.44 | 66.74 | 77.39 | 14 | 22 | 22 | |||||||||||||||
4 | 1.91 | 1.11 | 47.11 | 53.36 | 20 | 23 | 7 | |||||||||||||||||||
5 | 16 | 10 | 10 | 48 | 0 | 0 | 1 | 1.29 | 1.82 | 100.03 | 106.79 | 11 | 13 | 8 | ||||||||||||
6 | 64 | 13 | 9 | 48 | 0 | 0 | 1 | 1.68 | 1.28 | 56.01 | 68.87 | 26.5 | 29 | 5 | ||||||||||||
7 | 30 | 7 | 4 | 44 | 1.8 | 1.03 | 98.84 | 107.68 | 16.5 | 21 | 12 | |||||||||||||||
8 | 14 | 10 | 8 | 45 | 29 | 33 | 6 | |||||||||||||||||||
9 | 64 | 18 | 17 | 53 | 2 | 1 | 2 | 1.52 | 1.93 | 68.85 | 75.69 | 8.5 | 10.5 | 11 | ||||||||||||
10 | 44 | 12 | 11 | 47 | 3 | 1 | 4 | 1.6 | 1.8 | 87.52 | 141.79 | 27.5 | 16.5 | 25 | ||||||||||||
# | cVEMP Left 500 Hz | cVEMP Left 1 kHz | cVEMP Right 500 Hz | cVEMP Right 1 kHz | ||||||||||||||||||||||
n13 | p23 | Amplitude | Area | n13 | p23 | Amplitude | Area | n13 | p23 | Amplitude | Area | n13 | p23 | Amplitude | Area | |||||||||||
(ms) | (ms) | (µV) | (µVms) | (ms) | (ms) | (µV) | (µVms) | (ms) | (ms) | (µV) | (µVms) | (ms) | (ms) | (µV) | (µVms) | |||||||||||
1 | 12.2 | 18 | 183 | 2409 | 14 | 19.7 | 185 | 2605 | 13 | 18.4 | 313 | 3789 | 0 | 2938 | ||||||||||||
2 | 10.9 | 20.8 | 200 | 1957 | 11.8 | 20.3 | 91.8 | 1926 | 13 | 18.3 | 111 | 1826 | 12.6 | 20.2 | 170 | 1787 | ||||||||||
3 | 14 | 21.4 | 212 | 3379 | 12.5 | 20.9 | 269 | 3670 | 0 | 2690 | 0 | 2591 | ||||||||||||||
4 | 11.6 | 20.1 | 210 | 2419 | 12 | 18 | 198 | 2150 | 12.7 | 19.5 | 86.8 | 1536 | 12.9 | 18.3 | 134 | 1756 | ||||||||||
5 | 13.2 | 20 | 260 | 3307 | 12.6 | 22.5 | 348 | 4125 | 12.1 | 17.6 | 192 | 3257 | 12.8 | 18.8 | 280 | 2818 | ||||||||||
6 | 0 | 3917 | 13.2 | 18.5 | 246 | 3727 | 0 | 4403 | 12.8 | 16.8 | 233 | 4634 | ||||||||||||||
7 | 14.1 | 22 | 429 | 3937 | 13.4 | 20.9 | 544 | 4097 | 13.3 | 22 | 446 | 4397 | 12.6 | 20.1 | 367 | 4195 | ||||||||||
8 | 17.6 | 22.8 | 127 | 2428 | 10.4 | 13.8 | 110 | 2361 | 0 | 1473 | 1458 | |||||||||||||||
9 | 15.3 | 24.2 | 236 | 3026 | 14.4 | 22.9 | 242 | 3852 | 14.5 | 23.1 | 269 | 3710 | 14.7 | 23.1 | 187 | 4186 | ||||||||||
10 | 12.7 | 20.6 | 473 | 4135 | 13.9 | 21.1 | 422 | 5508 | 0 | 5364 | 0 | 5278 | ||||||||||||||
# | oVEMP Left 500 Hz | oVEMP Left 1 kHz | oVEMP Right 500 Hz | oVEMP Right 1 kHz | VEMP AR | |||||||||||||||||||||
n1 | p1 | base-n1 | n1-p1 | Area | n1 | p1 | base-n1 | n1-p1 | Area | n1 | p1 | base-n1 | n1-p1 | Area | n1 | p1 | base-n1 | n1-p1 | Area | cVEMP | oVEMP | |||||
(ms) | (ms) | amp. (µV) | amp. (µV) | (µVms) | (ms) | (ms) | amp. (µV) | amp. (µV) | (µVms) | (ms) | (ms) | amp. (µV) | amp. (µV) | (µVms) | (ms) | (ms) | amp. (µV) | amp. (µV) | (µVms) | 500 Hz | 1 kHz | 500 Hz | 1 kHz | |||
1 | 10.4 | 12.3 | 1.21 | 2.08 | 8.38 | 10.7 | 13.5 | 0.38 | 3.11 | 8.6 | 10.5 | 15.6 | 1.3 | 4.37 | 7.97 | 0 | 0 | 7.97 | 4.3 | 100.0 | 37.6 | 100.0 | ||||
2 | 10.2 | 15.6 | 7.28 | 12.8 | 3.69 | 9 | 15.1 | 6.97 | 11.2 | 4.24 | 10.3 | 16 | 2.3 | 3.53 | 5.26 | 9.05 | 15.6 | 2.56 | 4.55 | 3.27 | 25.5 | 33.2 | 67.5 | 31.0 | ||
3 | 11.1 | 14.9 | 0.93 | 1.43 | 4.58 | 10.9 | 14.2 | 1.21 | 3.85 | 7.34 | 10.7 | 15.5 | 2.85 | 4.24 | 9.82 | 0 | 0 | 5.32 | 100.0 | 100.0 | 16.2 | 100.0 | ||||
4 | 10.2 | 14 | 5.7 | 14.7 | 15.6 | 9.05 | 11.9 | 12.3 | 17.7 | 12.5 | 10.1 | 13.5 | 11.4 | 14.7 | 15 | 9.25 | 12.3 | 8.56 | 16.3 | 17.5 | 21.0 | 9.4 | 2.1 | 20.4 | ||
5 | 10.8 | 15.9 | 3.11 | 6.95 | 6.24 | 10 | 15.5 | 1.7 | 4.53 | 9.07 | 10.8 | 16.6 | 2.91 | 4.3 | 6.86 | 10.6 | 14.4 | 1 | 6.43 | 6.97 | 14.2 | 8.2 | 28.0 | 29.8 | ||
6 | 0 | 0 | 25 | 0 | 0 | 39.9 | 0 | 0 | 17.3 | 0 | 0 | 15.1 | NR | 13.6 | NR | NR | ||||||||||
7 | 10.8 | 16.8 | 4.72 | 10.3 | 10.8 | 9.8 | 16.1 | 7.63 | 15.8 | 10.7 | 10.9 | 16.8 | 4.05 | 8.73 | 7.13 | 9.9 | 13.5 | 5.38 | 9.95 | 11.1 | 3.6 | 20.6 | 12.4 | 24.9 | ||
8 | 11.3 | 13.8 | 2.23 | 3.69 | 7.2 | 12.5 | 16.7 | 4.48 | 4.26 | 12.3 | 0 | 0 | 9.25 | 0 | 0 | 8.87 | 100.0 | 100.0 | 100.0 | 100.0 | ||||||
9 | 0 | 0 | 8.96 | 0 | 0 | 16.7 | 0 | 0 | 4.77 | 0 | 0 | 6.7 | 3.7 | 16.8 | NR | NR | ||||||||||
10 | 9.9 | 12.6 | 1.91 | 4.08 | 10.2 | 9.2 | 12 | 0.99 | 3.08 | 6.15 | 0 | 0 | 6.74 | 0 | 0 | 5.54 | 100.0 | 100.0 | 100.0 | 100.0 |
References
- Streeten, D.H.P.; Anderson, G.H. Delayed Orthostatic Intolerance. Arch. Intern. Med. 1992, 152, 1066–1072. [Google Scholar] [CrossRef] [PubMed]
- Aoki, M.; Sakaida, Y.; Hayashi, H.; Yamada, N.; Mizuta, K.; Ito, Y. The orthostatic dysregulation of blood pressure in dizzy patients. J. Vestib. Res. 2008, 18, 223–229. [Google Scholar] [CrossRef] [PubMed]
- Ott, C.; Scholmerich, J. Extraintestinal manifestations and complications in IBD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 585–595. [Google Scholar] [CrossRef] [PubMed]
- Wasserbauer, M.; Mala, S.; Stechova, K.; Hlava, S.; Cernikova, P.; Stovicek, J.; Drabek, J.; Broz, J.; Pichlerova, D.; Kucerova, B.; et al. Dysfunction of peripheral somatic and autonomic nervous system in patients with severe forms of Crohn’s disease on biological therapy with TNFα inhibitors—A single center study. PLoS ONE 2023, 18, e0294441. [Google Scholar] [CrossRef]
- Ohlsson, B.; Sundkvist, G.; Lindgren, S. Subclinical sympathetic neuropathy appears early in the course of Crohn’s disease. BMC Gastroenterol. 2007, 7, 33. [Google Scholar] [CrossRef]
- Rutan, G.H.; Hermanson, B.; Bild, D.E.; Kittner, S.J.; LaBaw, F.; Tell, G.S. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992, 19, 508–519. [Google Scholar] [CrossRef]
- Freeman, R.; Wieling, W.; Axelrod, F.B.; Benditt, D.G.; Benarroch, E.; Biaggioni, I.; Cheshire, W.P.; Chelimsky, T.; Cortelli, P.; Gibbons, C.H.; et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 2011, 21, 69–72. [Google Scholar] [CrossRef]
- Wu, J.-S.; Yang, Y.-C.; Lu, F.-H.; Wu, C.-H.; Chang, C.-J. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens. Res. 2008, 31, 897–904. [Google Scholar] [CrossRef]
- Pena, C.; Moustafa, A.; Mohamed, A.-R.; Grubb, B. Autoimmunity in Syndromes of Orthostatic Intolerance: An Updated Review. J. Pers. Med. 2024, 14, 435. [Google Scholar] [CrossRef]
- Jacobson, G.P.; Newman, C.W. The Development of the Dizziness Handicap Inventory. Arch. Otolaryngol. Neck Surg. 1990, 116, 424–427. [Google Scholar] [CrossRef]
- Zigmond, A.S.; Snaith, R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983, 67, 361–370. [Google Scholar] [CrossRef] [PubMed]
- Zung, W.W.K. A Self-Rating Depression Scale. Arch. Gen. Psychiatry 1965, 12, 63–70. [Google Scholar] [CrossRef] [PubMed]
- Yesavage, J.A.; Brink, T.L.; Rose, T.L.; Lum, O.; Huang, V.; Adey, M.; Leirer, V.O. Development and validation of a geriatric depression screening scale: A preliminary report. J. Psychiatr. Res. 1982, 17, 37–49. [Google Scholar] [CrossRef] [PubMed]
- Sheikh, J.I.; Yesavage, J.A. 9/geriatric depression scale (Gds) recent evidence and development of a shorter version. Clin. Gerontol. 1986, 5, 165–173. [Google Scholar] [CrossRef]
- Detsky, M.E.; McDonald, D.R.; Baerlocher, M.O.; Tomlinson, G.A.; McCrory, D.C.; Booth, C.M. Does this patient with headache have a migraine or need neuroimaging? JAMA 2006, 296, 1274–1283. [Google Scholar] [CrossRef]
- Stewart, W.F.; Lipton, R.B.; Dowson, A.J.; Sawyer, J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001, 56, S20–S28. [Google Scholar] [CrossRef]
- Takeshima, T.; Sakai, F.; Suzuki, N.; Shimizu, T.; Igarashi, H.; Araki, N.; Manaka, S.; Nakashima, K.; Hashimoto, Y.; Iwata, M.; et al. A simple migraine screening instrument; Validation study in Japan. Jpn. J. Headache 2015, 42, 134–143. [Google Scholar]
- Olesen, J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia 2018, 38, 1–211. [Google Scholar]
- Schellong, F.; Lüderitz, B. Regulationsprüfung Des Kreislaufs Funktionelle Differentialdiagnose von Herz- und Gefässstörungen; Steinkopff: Berlin, Germany, 1954. [Google Scholar]
- Fanciulli, A.; Campese, N.; Wenning, G.K. The Schellong test: Detecting orthostatic blood pressure and heart rate changes in German-speaking countries. Clin. Auton. Res. 2019, 29, 363–366. [Google Scholar] [CrossRef]
- Japan Society of Neurovegetative Research Head-up tilt test and Orthostatic test. In Autonomic Nerve Function Test; Bunkodo: Tokyo, Japan, 2015.
- Schmäl, F.; Lübben, B.; Weiberg, K.; Stoll, W. The minimal ice water caloric test compared with established vestibular caloric test procedures. J. Vestib. Res. Equilib. Orientat. 2005, 15, 215–224. [Google Scholar] [CrossRef]
- Iwasaki, S.; Takai, Y.; Ozeki, H.; Ito, K.; Karino, S.; Murofushi, T. Extent of lesions in idiopathic sudden hearing loss with vertigo: Study using click and galvanic vestibular evoked myogenic potentials. Arch. Otolaryngol.—Head Neck Surg. 2005, 131, 857–862. [Google Scholar] [CrossRef] [PubMed]
- Fujimoto, C.; Murofushi, T.; Chihara, Y.; Suzuki, M.; Yamasoba, T.; Iwasaki, S. Novel subtype of idiopathic bilateral vestibulopathy: Bilateral absence of vestibular evoked myogenic potentials in the presence of normal caloric responses. J. Neurol. 2009, 256, 1488–1492. [Google Scholar] [CrossRef] [PubMed]
- Fujimoto, C.; Egami, N.; Kinoshita, M.; Sugasawa, K.; Yamasoba, T.; Iwasaki, S. Involvement of vestibular organs in idiopathic sudden hearing loss with vertigo: An analysis using oVEMP and cVEMP testing. Clin. Neurophysiol. 2015, 126, 1033–1038. [Google Scholar] [CrossRef]
- R Core Team. R Core Team R: A Language and Environment for Statistical Computing; R Core Team: Vienna, Austria, 2024. [Google Scholar]
- Stein, J.; Dignass, A.U. Management of iron deficiency anemia in inflammatory bowel disease—A practical approach. Ann. Gastroenterol. 2013, 26, 104–113. [Google Scholar]
- Mahadea, D.; Adamczewska, E.; Ratajczak, A.E.; Rychter, A.M.; Zawada, A.; Eder, P.; Dobrowolska, A.; Krela-Kaźmierczak, I. Iron deficiency anemia in inflammatory bowel diseases—A narrative review. Nutrients 2021, 13, 4008. [Google Scholar] [CrossRef]
- Abomhya, A.; Tai, W.; Ayaz, S.; Khan, F.; Saadedeen, W.; Ajala, O.; Mohamed, R. Iron Deficiency Anemia: An Overlooked Complication of Crohn’s Disease. J. Hematol. 2022, 11, 55–61. [Google Scholar] [CrossRef]
- Włodarczyk, M.; Makaro, A.; Prusisz, M.; Włodarczyk, J.; Nowocień, M.; Maryńczak, K.; Fichna, J.; Dziki, Ł. The Role of Chronic Fatigue in Patients with Crohn’s Disease. Life 2023, 13, 1692. [Google Scholar] [CrossRef]
- Bär, F.; Krause, T.; Stallmach, A.; Teich, N.; Maaser, C.; Maul, J.; Helwig, U.; Fellermann, K.; Büning, J. Cyclophosphamide Pulse Therapy in Severe Refractory Crohn’s Disease: A Retrospective Multicenter Case Series. Inflamm. Intest. Dis. 2018, 2, 139–146. [Google Scholar] [CrossRef]
- Ringer, M.; Lappin, S.L. Orthostatic Hypotension; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Zhao, S.; Tran, V.H. Postural Orthostatic Tachycardia Syndrome; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Murch, S.H.; Braegger, C.P.; Walker-Smith, J.A.; MacDonald, T.T. Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993, 34, 1705–1709. [Google Scholar] [CrossRef]
- Mudter, J.; Neurath, M.F. IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 2007, 13, 1016–1023. [Google Scholar] [CrossRef]
- Elsässer-Beile, U.; von Kleist, S.; Gerlach, S.; Gallati, H.; Mönting, J.S. Cytokine production in whole blood cell cultures of patients with crohn’s disease and ulcerative colitis. J. Clin. Lab. Anal. 1994, 8, 447–451. [Google Scholar] [CrossRef] [PubMed]
- Anka Idrissi, D.; Senhaji, N.; Aouiss, A.; Khalki, L.; Tijani, Y.; Zaid, N.; Marhoume, F.Z.; Naya, A.; Oudghiri, M.; Kabine, M.; et al. IL-1 and CD40/CD40L platelet complex: Elements of induction of Crohn’s disease and new therapeutic targets. Arch. Pharm. Res. 2021, 44, 117–132. [Google Scholar] [CrossRef] [PubMed]
- Dvorak, A.M.; Silen, W. Differentiation between Crohn’s disease and other inflammatory conditions by electron microscopy. Ann. Surg. 1985, 201, 53–63. [Google Scholar] [CrossRef]
- Geboes, K.; Collins, S. Structural abnormalities of the nervous system in Crohn’s disease and ulcerative colitis. Neurogastroenterol. Motil. 1998, 10, 189–202. [Google Scholar] [CrossRef]
- Straub, R.H.; Herfarth, H.; Falk, W.; Andus, T.; Schölmerich, J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J. Neuroimmunol. 2002, 126, 116–125. [Google Scholar] [CrossRef]
- Zawadka-Kunikowska, M.; Słomko, J.; Kłopocka, M.; Liebert, A.; Tafil-Klawe, M.; Klawe, J.J.; Newton, J.L.; Zalewski, P. Cardiac and autonomic function in patients with Crohn’s disease during remission. Adv. Med. Sci. 2018, 63, 334–340. [Google Scholar] [CrossRef]
- Ganguli, S.C.; Kamath, M.V.; Redmond, K.; Chen, Y.; Irvine, E.J.; Collins, S.M.; Tougas, G. A comparison of autonomic function in patients with inflammatory bowel disease and in healthy controls. Neurogastroenterol. Motil. 2007, 19, 961–967. [Google Scholar] [CrossRef]
- Banks, W.A.; Kastin, A.J.; Broadwell, R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2, 241–248. [Google Scholar] [CrossRef]
- Banks, W. Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology. Curr. Pharm. Des. 2005, 11, 973–984. [Google Scholar] [CrossRef]
- Kim, J.S.; Chen, M.H.; Wang, H.E.; Lu, C.L.; Wang, Y.P.; Zhang, B. Inflammatory Bowel Disease and Neurodegenerative Diseases. Gut Liver 2023, 17, 495–504. [Google Scholar] [CrossRef]
- Puckett, Y.; Gabbar, A.; Bokhari, A.A. Prednisone; StatPearls Publishing: Treasure Island, FL, USA, 2024; ISBN 9780080552323. [Google Scholar]
- Roifman, I.; Sun, Y.C.; Fedwick, J.P.; Panaccione, R.; Buret, A.G.; Liu, H.; Rostom, A.; Anderson, T.J.; Beck, P.L. Evidence of Endothelial Dysfunction in Patients With Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2009, 7, 175–182. [Google Scholar] [CrossRef] [PubMed]
- Gravina, A.G.; Dallio, M.; Masarone, M.; Rosato, V.; Aglitti, A.; Persico, M.; Loguercio, C.; Federico, A. Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets. Oxid. Med. Cell. Longev. 2018, 2018, 2568569. [Google Scholar] [CrossRef] [PubMed]
- Dettmer, M.; Hegemann, I.; Hegemann, S.C.A. Extraintestinal Crohn’s disease mimicking autoimmune inner ear disease: A histopathological approach. Audiol. Neurotol. 2010, 16, 36–40. [Google Scholar] [CrossRef]
- Vavricka, S.R.; Greuter, T.; Scharl, M.; Mantzaris, G.; Shitrit, A.B.; Filip, R.; Karmiris, K.; Thoeringer, C.K.; Boldys, H.; Wewer, A.V.; et al. Cogan’s Syndrome in Patients with Inflammatory Bowel Disease—A Case Series. J. Crohns. Colitis 2015, 9, 886–890. [Google Scholar] [CrossRef]
- Fousekis, F.S.; Saridi, M.; Albani, E.; Daniel, F.; Katsanos, K.H.; Kastanioudakis, I.G.; Christodoulou, D.K. Ear Involvement in Inflammatory Bowel Disease: A Review of the Literature. J. Clin. Med. Res. 2018, 10, 609–614. [Google Scholar] [CrossRef]
- Wijdicks, E.F.M. Neurotoxicity of immunosuppressive drugs. Liver Transplant. 2001, 7, 937–942. [Google Scholar] [CrossRef]
- Anghel, D.; Tanasescu, R.; Campeanu, A.; Lupescu, I.; Podda, G.; Bajenaru, O. Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica 2013, 8, 170–175. [Google Scholar]
- Claydon, V.E.; Hainsworth, R. Postural sway in patients with syncope and poor orthostatic tolerance. Heart 2006, 92, 1688–1689. [Google Scholar] [CrossRef]
- Williams, E.L.; Hockin, B.C.D.; Heeney, N.D.; Elabd, K.; Chong, H.; Blaber, A.P.; Robinovitch, S.N.; Parsons, I.T.; Claydon, V.E. Exaggerated postural sway improves orthostatic cardiovascular and cerebrovascular control. Front. Cardiovasc. Med. 2023, 10, 1040036. [Google Scholar] [CrossRef]
- Funato, T.; Aoi, S.; Tomita, N.; Tsuchiya, K. Smooth enlargement of human standing sway by instability due to weak reaction floor and noise. R. Soc. Open Sci. 2016, 3, 150570. [Google Scholar] [CrossRef]
- Nagai, K.; Aoyama, T.; Yamada, M.; Izeki, M.; Fujibayashi, S.; Takemoto, M.; Nishiguchi, S.; Tsuboyama, T.; Neo, M. Quantification of changes in gait characteristics associated with intermittent claudication in patients with lumbar spinal stenosis. J. Spinal Disord. Tech. 2014, 27, E136–E142. [Google Scholar] [CrossRef] [PubMed]
- Ford, S.; Finkel, A.G.; Isaacs, K.L. Migraine in patients with inflammatory bowel disorders. J. Clin. Gastroenterol. 2009, 43, 499. [Google Scholar] [CrossRef] [PubMed]
- Dimitrova, A.K.; Ungaro, R.C.; Lebwohl, B.; Lewis, S.K.; Tennyson, C.A.; Green, M.W.; Babyatsky, M.W.; Green, P.H. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 2013, 53, 344–355. [Google Scholar] [CrossRef] [PubMed]
- Moisset, X.; Bommelaer, G.; Boube, M.; Ouchchane, L.; Goutte, M.; Dapoigny, M.; Dallel, R.; Guttmann, A.; Clavelou, P.; Buisson, A. Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study. Eur. J. Pain 2017, 21, 1550–1560. [Google Scholar] [CrossRef]
- Lee, C.H.; Han, K.; Lee, H.J.; Yu, H.; Kim, S.; Choi, K.; Koh, S.J.; Im, J.P.; Kim, J.S. Migraine is associated with the development of adult patients with inflammatory bowel disease: A nationwide, population-based study. Sci. Rep. 2024, 14, 1157. [Google Scholar] [CrossRef]
- Krueger, G.G.; Langley, R.G.; Leonardi, C.; Yeilding, N.; Guzzo, C.; Wang, Y.; Dooley, L.T.; Lebwohl, M. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. N. Engl. J. Med. 2007, 356, 580–592. [Google Scholar] [CrossRef]
- Leonardi, C.L.; Kimball, A.B.; Papp, K.A.; Yeilding, N.; Guzzo, C.; Wang, Y.; Li, S.; Dooley, L.T.; Gordon, K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371, 1665–1674. [Google Scholar] [CrossRef]
- Sandborn, W.J.; Feagan, B.G.; Danese, S.; O’Brien, C.D.; Ott, E.; Marano, C.; Baker, T.; Zhou, Y.; Volger, S.; Tikhonov, I.; et al. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm. Bowel Dis. 2021, 27, 994–1007. [Google Scholar] [CrossRef]
- D’Amico, F.; Peyrin-Biroulet, L.; Danese, S. Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm. J. Crohns. Colitis 2022, 16, ii30–ii41. [Google Scholar] [CrossRef]
- Feagan, B.G.; Sandborn, W.J.; Gasink, C.; Jacobstein, D.; Lang, Y.; Friedman, J.R.; Blank, M.A.; Johanns, J.; Gao, L.-L.; Miao, Y.; et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2016, 375, 1946–1960. [Google Scholar] [CrossRef]
- Sandborn, W.J.; Rutgeerts, P.; Gasink, C.; Jacobstein, D.; Zou, B.; Johanns, J.; Sands, B.E.; Hanauer, S.B.; Targan, S.; Ghosh, S.; et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment. Pharmacol. Ther. 2018, 48, 65–77. [Google Scholar] [CrossRef] [PubMed]
- Böhm, S.K.; Kruis, W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin. Exp. Gastroenterol. 2014, 7, 369–383. [Google Scholar] [CrossRef] [PubMed]
- Murphy, W.; Liu, S.; Javadiyan, S.; Vyskocil, E.; Feizi, S.; Callejas, C.; Wormald, P.-J.; Vreugde, S.; Psaltis, A.J. An In Vitro Study Evaluating the Safety of Mesalazine on Human Nasoepithelial Cells. Int. J. Mol. Sci. 2024, 25, 2796. [Google Scholar] [CrossRef] [PubMed]
- Prantera, C.; Cottone, M.; Pallone, F.; Annese, V.; Franzè, A.; Cerutti, R.; Bianchi Porro, G. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: Results of a randomized, multicenter trial. Gastroenterology 1999, 116, 521–526. [Google Scholar] [CrossRef]
- Ford, A.C.; Kane, S.V.; Khan, K.J.; Achkar, J.-P.; Talley, N.J.; Marshall, J.K.; Moayyedi, P. Efficacy of 5-aminosalicylates in Crohn’s disease: Systematic review and meta-analysis. Am. J. Gastroenterol. 2011, 106, 617–629. [Google Scholar] [CrossRef]
- Gaspar, R.; Branco, C.C.; Macedo, G. Liver manifestations and complications in inflammatory bowel disease: A review. World J. Hepatol. 2021, 13, 1956–1967. [Google Scholar] [CrossRef]
- Martínez-Domínguez, S.J.; García-Mateo, S.; Gargallo-Puyuelo, C.J.; Gallego Llera, B.; Refaie, E.; Callau, P.; Mendi, C.; Baptista, P.M.; Hernández Ainsa, M.; Arroyo-Villarino, M.T.; et al. Crohn’s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease. Eur. J. Intern. Med. 2024, 120, 99–106. [Google Scholar] [CrossRef]
- Liu, W.; Wang, L.; Huang, X.; He, W.; Song, Z.; Yang, J. Impaired orthostatic blood pressure stabilization and reduced hemoglobin in chronic kidney disease. J. Clin. Hypertens. 2019, 21, 1317–1324. [Google Scholar] [CrossRef]
- Jarjour, I.T.; Jarjour, L.K. Low iron storage in children and adolescents with neurally mediated syncope. J. Pediatr. 2008, 153, 40–44. [Google Scholar] [CrossRef]
- Jarjour, I.T.; Jarjour, L.K. Low iron storage and mild anemia in postural tachycardia syndrome in adolescents. Clin. Auton. Res. 2013, 23, 175–179. [Google Scholar] [CrossRef]
- Siva, S.; Rubin, D.T.; Gulotta, G.; Wroblewski, K.; Pekow, J. Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2017, 23, 152–157. [Google Scholar] [CrossRef] [PubMed]
- Soltani, Z.; Rafiei, F.; EBRAHIMi, A.; Rafiei, R. The Prevalence of Zinc Deficiency in Crohn’s Disease Patients. Maedica 2021, 16, 29–33. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, T.; Higashi, A.; Takano, S.; Akagi, M.; Matsuda, I. Zinc clearance correlates with clinical severity of Crohn’s disease—A kinetic study. Dig. Dis. Sci. 1988, 33, 1520–1524. [Google Scholar] [CrossRef]
- Kita, K.; Hirayama, K. Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug. Neurology 1988, 38, 1095–1099. [Google Scholar] [CrossRef] [PubMed]
- Parsaik, A.K.; Singh, B.; Altayar, O.; Mascarenhas, S.S.; Singh, S.K.; Erwin, P.J.; Murad, M.H. Midodrine for orthostatic hypotension: A systematic review and meta-analysis of clinical trials. J. Gen. Intern. Med. 2013, 28, 1496–1503. [Google Scholar] [CrossRef]
- Sakata, M.; Egami, H. Successful treatment of orthostatic dysregulation with Japanese (Kampo) herbal medicine ryokeijutsukanto. Explore 2021, 17, 521–524. [Google Scholar] [CrossRef]
- Momodu, I.I.; Okafor, C.N. Orthostatic Syncope (Archived); StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Jankovic, J.; Gilden, J.L.; Hiner, B.C.; Kaufmann, H.; Brown, D.C.; Coghlan, C.H.; Rubin, M.; Fouad-Tarazi, F.M. Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am. J. Med. 1993, 95, 38–48. [Google Scholar] [CrossRef]
- Low, P.A.; Gilden, J.L.; Freeman, R.; Sheng, K.N.; McElligott, M.A. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: A randomized, double-blind multicenter study. JAMA 1997, 277, 1046–1051. [Google Scholar] [CrossRef]
non-IBD (n = 211) | IBD (n = 10) | p Value | |
---|---|---|---|
Sex [Male] | 83 (39.3) | 8 (80.0) | 0.02 * |
Age | 62.5 ± 18.8 | 46.7 ± 12.8 | 0.01 * |
OD | 23/211 (11%) | 5/10 (50%) | <0.01 * |
Psychogenic vertigo | 98/211 (47%) | 7/10 (70%) | 0.20 |
Migraine | 36/211 (17%) | 2/10 (20%) | 0.68 |
DHI | 32.1 ± 21.7 | 36.4 ± 21.2 | 0.56 |
HADS/A | 6.9 ± 4.1 | 9.1 ± 4.9 | 0.22 |
HADS/D | 6.1 ± 4.0 | 8.9 ± 3.8 | 0.06 |
SDS | 42.4 ± 9.8 | 44.0 ± 5.9 | 0.48 |
POUNDing | 0.7 ± 1.3 | 0.8 ± 1.3 | 0.86 |
MIDAS | 1.4 ± 1.0 | 1.7–1.2 | 0.63 |
Migraine screener [positive] | 30/139 (22%) | 2/6 (33%) | 0.61 |
Romberg rate (velocity, rubber) | 1.8 ± 0.5 | 1.6 ± 0.2 | 0.01 * |
Rubber ratio (eyes closed, velocity) | 1.8 ± 0.8 | 1.5 ± 0.3 | 0.04 * |
Total length (eyes opened) [cm] | 102.1 ± 52.1 | 76.1 ± 18.4 | <0.01 * |
Total length (eyes closed) [cm] | 145.3 ± 76.6 | 90.4 ± 26.3 | <0.01 * |
Caloric testing [abnormal] | 106/208 (51%) | 2/10 (20%) | 0.14 |
cVEMP 500 Hz [abnormal] | 134/205 (65%) | 4/10 (40%) | 0.17 |
cVEMP 1 kHz [abnormal] | 135/205 (65%) | 5/10 (50%) | 0.32 |
oVEMP 500 Hz [abnormal] | 167/205 (82%) | 6/10 (60%) | 0.11 |
oVEMP 1 kHz [abnormal] | 174/205 (85%) | 6/10 (60%) | 0.06 |
Estimate | Std. Error | z Value | Pr (>|z) | |
---|---|---|---|---|
(Intercept) | −1.5332 | 0.70395 | −2.178 | 0.02941 * |
Sex | 0.2109 | 0.43231 | 0.488 | 0.62565 |
Age | −0.01073 | 0.01106 | −0.97 | 0.33224 |
IBD | 1.86558 | 0.70719 | 2.638 | 0.00834 ** |
(a) Romberg Rate (Velocity, Rubber) | (b) Rubber Ratio (Eyes Closed, Velocity) | ||||||||
Estimate | Std. Error | t Value | Pr (>|t|) | Estimate | Std. Error | t Value | Pr (>|t|) | ||
(Intercept) | 2.1037 | 0.1385 | 15.1860 | <2 × 10−16 *** | (Intercept) | 1.7630 | 0.2166 | 8.1400 | 8.05 × 10−14 *** |
Sex | 0.1247 | 0.0786 | 1.5850 | 0.1148 | Sex | 0.0244 | 0.1230 | 0.1980 | 0.8430 |
Age | −0.0055 | 0.0021 | −2.6160 | 0.0097 ** | Age | 0.0001 | 0.0033 | 0.0190 | 0.9850 |
IBD | −0.3656 | 0.1795 | −2.0370 | 0.0432 * | IBD | −0.2882 | 0.2806 | −1.0270 | 0.3060 |
(c) Total Length (Eyes Opened) | (d) Total Length (Eyes Closed) | ||||||||
Estimate | Std. Error | t Value | Pr (>|t|) | Estimate | Std. Error | t Value | Pr (>|t|) | ||
(Intercept) | 25.2882 | 12.2693 | 2.0610 | 0.04059 * | (Intercept) | 66.4318 | 18.6957 | 3.5530 | 0.000477 *** |
Sex | 18.8269 | 6.8645 | 2.7430 | 0.00665 ** | Sex | 35.3345 | 10.5143 | 3.3610 | 0.000935 *** |
Age | 1.1227 | 0.1838 | 6.1070 | 5.19 × 10−9 *** | Age | 1.0513 | 0.2815 | 3.7350 | 0.000246 *** |
IBD | −14.8325 | 16.7397 | −0.8860 | 0.3767 | IBD | −51.2522 | 25.4190 | −2.0160 | 0.045134 * |
# | Sex | Age | IBD | Disease Period | Diagnosis |
of IBD (years) | |||||
1 | M | 49 | CD | 24 | BPPV |
2 | M | 44 | CD | 17 | BPPV after traffic trauma |
3 | M | 49 | CD | 28 | Peripheral vestibular dysfunction |
4 | M | 22 | CD | 6 | Psychogenic vertigo, Delayed endolymphatic hydrops |
5 | M | 51 | CD | 30 | Psychogenic vertigo, OD |
6 | M | 60 | CD | 27 | Psychogenic vertigo, OD |
7 | M | 63 | UC | 4 | Psychogenic vertigo, OD |
8 | M | 58 | CD | 22 | Psychogenic vertigo, OD, Parkinson’s disease |
9 | F | 38 | CD | 18 | Psychogenic vertigo, Migraine |
10 | F | 33 | CD | 18 | Meniere’s disease (probable), Migraine, OD |
# | Prescriptions Related to IBD | Prescriptions Related to Dizziness | |||
1 | Mesalazine, Budesonide (enema) | − | |||
2 | Mesalazine | − | |||
3 | Mesalazine, Risankizumab | − | |||
4 | Mesalazine, Salazosulfapyridine, Metronidazole, Azathioprine | Amezinium, Domperidone, Hangebyakujutsu temmato, Goshuyu, Saireito | |||
5 | Mesalazine | − | |||
6 | Mesalazine, Ustekinumab | Betahistine, Ryokeijutukanto | |||
7 | Salazosulfapyridine, Mesalazine | Betahistine | |||
8 | Salazosulfapyridine, Ustekinumab | Midodrine, Diphenidol, Ryokeijutukanto | |||
9 | Mesalazine | Hangebyakujutsu temmato, Goshuyu | |||
10 | Ustekinumab | Valproate, Chlorpheniramine, Acetaminophen, Midodrine, Goshuyu, Tokishakuyakusan |
# | OD | Days | TP | Alb | AST | ALT | LDH | ALP | gGTP | T.Bil | D.Bil | Amy | T-Chol | HDL | LDL | BUN | Cre | CRP | Zn | Fe | VB12 | Na | K | Cl | Hb | RBC | Hct |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | − | −33 | 7.7 | 4.4 | 17 | 19 | 164 | 82 | 17 | 0.1 | 78 | 105 | 12.3 | 471 | 39.8 | ||||||||||||
2 | − | 68 | 6.3 | 3.8 | 37 | 66 | 358 | 99 | 65 | 12 | 1.1 | 1 | 63 | 140 | 3.7 | 108 | 13.5 | 449 | 38.4 | ||||||||
3 | − | −12 | 6.8 | 4 | 22 | 26 | 173 | 134 | 115 | 0.8 | 0.1 | 70 | 122 | 19 | 1.02 | 0.1 | 86 | 211 | 143 | 4.2 | 109 | 14.5 | 476 | 44.6 | |||
4 | − | 219 | 7.2 | 4.3 | 21 | 20 | 199 | 53 | 38 | 1.2 | 0 | 90 | 98 | 32 | 47 | 6 | 0.88 | 0.1 | 139 | 4 | 105 | 15.8 | 526 | 45.1 | |||
5 | + | −61 | 7.9 | 4.1 | 40 | 47 | 135 | 102 | 54 | 101 | 143 | 54 | 56 | 11 | 1.03 | 0.1 | 75 | 107 | 279 | 139 | 3.3 | 98 | 14.4 | 479 | 41.7 | ||
6 | + | −19 | 6.9 | 3.7 | 22 | 15 | 185 | 90 | 10 | 0.8 | 0.1 | 75 | ≤50 | 142 | 4.1 | 104 | 13.8 | 464 | 42.4 | ||||||||
7 | + | −10 | 7.6 | 4.4 | 24 | 25 | 144 | 77 | 19 | 68 | 240 | 16 | 0.98 | 0.1 | 113 | 144 | 4.2 | 107 | 16.4 | 511 | 48.3 | ||||||
8 | + | −14 | 7 | 4.3 | 26 | 16 | 247 | 53 | 24 | 0.5 | 0 | 87 | 181 | 71 | 97 | 25 | 0.97 | 0.1 | 69 | 112 | 140 | 3.9 | 101 | 13.6 | 424 | 40.9 | |
9 | − | −28 | 7.2 | 3.5 | 17 | 14 | 130 | 73 | 25 | 0.4 | 209 | 193 | 71 | 81 | 9 | 0.49 | 0.7 | 64 | 56 | 141 | 4 | 105 | 12 | 475 | 39.1 | ||
10 | + | 0 | 7.9 | 3.5 | 20 | 18 | 128 | 76 | 10 | 105 | 7 | 0.62 | 0.1 | 89 | 42 | 156 | 138 | 3.9 | 106 | 11.7 | 444 | 37.3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kamogashira, T.; Nakada, T.; Kanaya, K. A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic. J. Clin. Med. 2025, 14, 341. https://doi.org/10.3390/jcm14020341
Kamogashira T, Nakada T, Kanaya K. A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic. Journal of Clinical Medicine. 2025; 14(2):341. https://doi.org/10.3390/jcm14020341
Chicago/Turabian StyleKamogashira, Teru, Tomoaki Nakada, and Kaori Kanaya. 2025. "A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic" Journal of Clinical Medicine 14, no. 2: 341. https://doi.org/10.3390/jcm14020341
APA StyleKamogashira, T., Nakada, T., & Kanaya, K. (2025). A Study of Dizziness or Vertigo Cases Associated with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) in a Vertigo Outpatient Clinic. Journal of Clinical Medicine, 14(2), 341. https://doi.org/10.3390/jcm14020341